Imatinib CAS#152459-95-5

Imatinib CAS#152459-95-5 is a kind of oral drugs used for the treatment of the chronic myelogenous leukemia (abbreviated CML) of positive symptoms of Philadelphia chromosome (Ber-Abl). It is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon. CML is a kind of hematopoietic stem cell disease caused by the DNA abnormalities in the bone marrow stem cells. DNA abnormalities will produce abnormal proteins and interfere with the normal generation process of the white blood cells in the bone marrow, resulting in the sharp increase in the number of white blood cells. CML is divided into three phases including chronic phase, accelerated phase and crisis phase with the average survival period of the patients in crisis phase being only 2-3 months.
Imatinib CAS#152459-95-5 is also effective in treating the gastrointestinal stromal tumor with the efficiency being about 50%.

Imatinib can be used for the treatment of the chronic myelogenous leukemia (abbreviated CML) of positive symptoms of Philadelphia chromosome (Ber-Abl). It is suitable for being applied to adult patients in acute transformation phase, accelerated phase, and chronic phase with treatment failure with interferon.

Imatinib is a benzamide obtained by formal condensation of the carboxy group of 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid with the primary aromatic amino group of 4-methyl-N(3)-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine. Used (as its mesylate salt) for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours. It has a role as an apoptosis inducer, a tyrosine kinase inhibitor and an antineoplastic agent. It is a N-methylpiperazine, a member of pyridines, a member of benzamides, an aromatic amine and a member of pyrimidines. It is functionally related to a benzamide.

Hot Tags: Imatinib CAS#152459-95-5, China Imatinib CAS#152459-95-5 manufacturers, suppliers, CAS 56 75 7,